title: FGFR1 and WT1 are markers of human prostate cancer progression.
abstract: BACKGROUND
  Androgen-independent prostate adenocarcinomas are responsible for about 6% of overall cancer deaths in men.
  
  
  METHODS
  We used DNA microarrays to identify genes related to the transition between androgen-dependent and androgen-independent stages in the LuCaP 23.1 xenograft model of prostate adenocarcinoma. The expression of the proteins encoded by these genes was then assessed by immunohistochemistry on tissue microarrays (TMA) including human prostate carcinoma samples issued from 85 patients who had undergone radical prostatectomy.
  
  
  RESULTS
  FGFR1, TACC1 and WT1 gene expression levels were associated with the androgen-independent stage in xenografts and human prostate carcinoma samples. MART1 protein expression was correlated with pT2 tumor stages.
  
  
  CONCLUSIONS
  Our results suggest that each of these four genes may play a role, or at least reflect a stage of prostate carcinoma growth/development/progression.
authors.affiliation: Centre de Recherche en Cancérologie de Marseille, Département d'Oncologie Moléculaire, UMR599 Inserm et Institut Paoli-Calmettes, Marseille, France. devilard@ciml.univ-mrs.fr
authors.forename: Elizabeth
authors.initials: E
authors.lastname: Devilard
authors.forename: Franck
authors.initials: F
authors.lastname: Bladou
authors.forename: Olivier
authors.initials: O
authors.lastname: Ramuz
authors.forename: Gilles
authors.initials: G
authors.lastname: Karsenty
authors.forename: Jean-Philippe
authors.initials: JP
authors.lastname: Dalès
authors.forename: Gwenaëlle
authors.initials: G
authors.lastname: Gravis
authors.forename: Catherine
authors.initials: C
authors.lastname: Nguyen
authors.forename: François
authors.initials: F
authors.lastname: Bertucci
authors.forename: Luc
authors.initials: L
authors.lastname: Xerri
authors.forename: Daniel
authors.initials: D
authors.lastname: Birnbaum
mesh_terms: D000230:Adenocarcinoma / Q000378:metabolism* / Q000473:pathology*; D000818:Animals; D000951:Antigens, Neoplasm / Q000378:metabolism; D014408:Biomarkers, Tumor / Q000302:isolation & purification* / Q000378:metabolism; D018450:Disease Progression; D005326:Fetal Proteins / Q000378:metabolism; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D007150:Immunohistochemistry; D058965:MART-1 Antigen; D008297:Male; D051379:Mice; D008869:Microtubule-Associated Proteins / Q000378:metabolism; D008875:Middle Aged; D008954:Models, Biological; D009363:Neoplasm Proteins / Q000378:metabolism; D009367:Neoplasm Staging / Q000379:methods; D009687:Nuclear Proteins / Q000378:metabolism; D020411:Oligonucleotide Array Sequence Analysis; D011471:Prostatic Neoplasms / Q000378:metabolism* / Q000473:pathology*; D051496:Receptor, Fibroblast Growth Factor, Type 1 / Q000378:metabolism*; D025721:WT1 Proteins / Q000378:metabolism*; D023041:Xenograft Model Antitumor Assays
chemical_list: D000951:Antigens, Neoplasm; D014408:Biomarkers, Tumor; D005326:Fetal Proteins; D058965:MART-1 Antigen; C548667:MLANA protein, human; D008869:Microtubule-Associated Proteins; C548668:Mlana protein, mouse; D009363:Neoplasm Proteins; D009687:Nuclear Proteins; C120584:TACC1 protein, human; D025721:WT1 Proteins; D051496:Receptor, Fibroblast Growth Factor, Type 1